Literature DB >> 3134897

Dyslipoproteinemia in pediatric systemic lupus erythematosus.

N T Ilowite1, P Samuel, E Ginzler, M S Jacobson.   

Abstract

Patients with systemic lupus erythematosus are at increased risk for premature atherosclerosis. We examined one possible etiologic factor, dyslipoproteinemia, both before and after corticosteroid therapy. We identified 2 distinct patterns of dyslipoproteinemia. One is attributable to active disease; the other is attributable, in part, to corticosteroid therapy. The dyslipoproteinemia of active disease consists of depressed high density lipoprotein cholesterol and apoprotein A-I with elevated very low density lipoprotein cholesterol and triglyceride, while the dyslipoproteinemia after corticosteroid therapy consists of increased total cholesterol, very low density lipoprotein cholesterol, and triglyceride. The possible pathophysiologic mechanisms responsible for these patterns, as well as the possible roles in premature atherosclerosis seen in systemic lupus erythematosus patients, are discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134897     DOI: 10.1002/art.1780310706

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  31 in total

1.  Increased risk of death in pediatric and adult patients with ESRD secondary to lupus.

Authors:  Sangeeta Sule; Barbara Fivush; Alicia Neu; Susan Furth
Journal:  Pediatr Nephrol       Date:  2010-10-03       Impact factor: 3.714

2.  Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies.

Authors:  Sara Kashef; Mohammad Mehdi Ghaedian; Akbar Rajaee; Abbas Ghaderi
Journal:  Rheumatol Int       Date:  2006-08-30       Impact factor: 2.631

Review 3.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

4.  Pediatric lupus--are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus?

Authors:  Rina Mina; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2010-02       Impact factor: 2.670

5.  The heart in systemic lupus erythematosus.

Authors:  R A Barker
Journal:  BMJ       Date:  1989-07-22

Review 6.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 7.  Pharmacotherapy of lupus nephritis in children: a recommended treatment approach.

Authors:  Alexa Adams; Emma Jane MacDermott; Thomas J A Lehman
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease.

Authors:  S M Jones; C P Harris; J Lloyd; C A Stirling; J P Reckless; N J McHugh
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

9.  Polymorphism of the beta3-adrenergic receptor and lipid profile in patients with rheumatoid arthritis and systemic lupus erythematosus treated with chloroquine.

Authors:  J F Muñoz-Valle; M Vázquez-Del Mercado; S Ruiz-Quezada; E Oregón-Romero; R E Navarro-Hernández; J Ramírez-Barragán; G Martínez-Bonilla; G Bernard-Medina; B E Bastidas-Ramírez; B Ruiz-Madrigal; A Panduro
Journal:  Rheumatol Int       Date:  2003-03-12       Impact factor: 2.631

10.  Plasma lipids and lipoproteins in juvenile chronic arthritis.

Authors:  A Bakkaloglu; B Kirel; S Ozen; U Saatçi; N Beşbaş
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.